Aerovate Therapeutics Inc...

NASDAQ: AVTE · Real-Time Price · USD
2.68
0.00 (0.00%)
At close: Apr 28, 2025, 3:59 PM

Aerovate Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
n/a 96K 68K n/a
Gross Profit
n/a -96K -68K -15K
Operating Income
-74.6M -81.41M -53.24M -23.02M
Interest Income
5.04M 5.95M 1.83M 65K
Pretax Income
-69.57M -75.47M -51.49M -22.96M
Net Income
-69.63M -75.52M -51.51M -22.96M
Selling & General & Admin
21.41M 17.19M 14.62M 8.04M
Research & Development
53.19M 64.22M 38.62M 14.99M
Other Expenses
n/a n/a -79K -3K
Operating Expenses
74.6M 81.41M 53.24M 23.02M
Interest Expense
n/a n/a n/a 65K
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
74.6M 81.41M 53.24M 23.02M
Income Tax Expense
55K 56K 25K 3K
Shares Outstanding (Basic)
28.58M 26.33M 24.47M 24.41M
Shares Outstanding (Diluted)
28.58M 26.33M 24.47M 24.41M
EPS (Basic)
-2.44 -2.87 -2.1 -1.87
EPS (Diluted)
-2.44 -2.87 -2.1 -1.87
EBITDA
-74.31M -81.31M -53.17M -23.01M
EBIT
-74.6M -81.41M -53.24M -23.02M
Depreciation & Amortization
282K 96K 68K 15K